We hypothesized that in cancer cells the loss of expression of the SMARCB1 protein was due to a somatic mosaic aneuploidy involving r22 and including SMARCB1, as described by Byers et al. (11), followed by a second-hit. This evidence concerns the gene SMARCB1 and cancer.